Background: Alternating chemotherapy and radiotherapy is a minor variation of concurrent chemoradiation. This schedule has been tested in advanced head and neck cancer and has shown superiority over standard radiation in some randomized trials with only marginaly greater toxicity. In this study the efficacy and toxicity of alternating chemotherapy and radiotherapy in advanced head and neck cancer was evaluated.
1
. Demographic and geographic factors as well as exposure to different carcinogens (e.g. nicotine, alcohol, viruses) contribute to the differential incidence of these tumors 2 .
As a rule, early-stage (stage I and II) HNC should be managed with a single modality, while advanced tumors are managed with multimodality therapy. Advanced hypopharyngeal or laryngeal squamous cell carcinomas are preferentially managed by surgery followed by radiotherapy or concurrent chemoradiation as organ preservation 3 .
Rapidly alternating chemotherapy and radiotherapy (ACR) is a minor variation of concurrent chemoradiation(CCR) aimed at minimizing toxicity. This scheduling allows uninterrupted treatment of the tumor, with radiotherapy administered during the pauses between cycles of chemotherapy 4 . One of the first randomized trials showing a significant survival advantage induced by chemoradiation in advanced (HNC) was one of rapidly alternating chemotherapy and radiotherapy 5 .
Decreasing chemoradiation induced toxicity is a major objective in (HNC). Chemoradiation has proven to be superior to radiotherapy alone, but treatment-related toxicities are higher, and an expert staff is required to deliver this complex treatment modality 6, 7 .
The objective of the present study was to assess the efficacy of alternating chemoradiotherapy, treatment toxicity, survival and prognostic factors of patients with locally advanced head and neck cancer.
PAtIEnS And MEtHodS

Selection of patients:
Patients were selected if they met the following criteria: histopathologically-proven squamous-cell carcinoma of the larynx or hypopharynx; stage III and IVA according to the American Joint Committe (AJCC) 2002 staging system, age <70, Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1, no previous surgery, radiotherapy and/or chemotherapy, and written informed consent. All eligible patients were included in the study.
Pretreatment evaluation included complete history, physical and ENT examination, complete blood count, liver and kidney function tests, chest X-ray. Computerized tomography and/or sonogram were performed when indicated.
treatment:
Radiotherapy consisted of 60 Gy (two-dimensional treatment) delivered as a daily single dose of 2 Gy, five times a week (acceptable dose with ACR), during weeks 2-3, 5-6, and 8-9(two-dimensions). Patients were treated with 6 MV photons. The primary site and upper-midneck nodes were treated with shrinking field technique with lateral parallel opposed photon fields (50Gy). The lower neck-supraclavicular regions were treated with an oppositional antero-posterior field (50 Gy). Areas of macroscopic disease were boosted for an additional 10 Gy at 2 Gy per fraction. The dose to the spinal cord was to be limited to 40 Gy.
Chemotherapy regimen consisted of vinblastine 6 mg/m 2 IV followed 6 hours later by bleomycin 30 IU IM day 1, methorexate 200mg IV day 2, leucovorin rescue 5 mg/m 2 IM every 6 hours day 3. Chemotherapy was given during weeks 1, 4, 7, 10.
Evaluation of response and toxicity:
Response was assessed 6 weeks after the end of treatment by repeating the method for staging according to World Health Organization criteria. Toxicities were evaluated according to EORTC/RTOG toxicity criteria 1995 and National Cancer Institute (NCI) common toxicity criteria version 2.0, 1998.
Statistical methods:
The primary end point of this study was complete response rate assessment. Response was assessed according to World Health Organization (WHO) criteria 8 . Secondary end points were overall survival and disease-free survival. Chi-square test was used to compare differences in distribution of frequencies among various groups of response. P-value 0.05 was considered significant. Overall survival and disease-free survival were calculated using Kaplan-Meier method 9 .
Disease-free survival was calculated from the time of treatment beginning until the time of disease progression at any site including the occurrence of metastases.
Overall survival was calculated from the time of treatment beginning until time of death or last follow-up.
rESuLtS
From December 2002 to July 2005 at Oncology Department in Assiut University Hospital, 50 patients with locoregionally advanced laryngeal and hypopharyngeal cancer entered the study. Sample size was estimated based on the prevelance of squamous cell carcinoma cases who attended the hospital. All patients were examined to sort out the eligible cases. All eligible cases were included in the study.
Table (1) shows the main patients characteristics.
Tumor and nodal staging is presented in Table ( 2).
Anatomical site and pathological tumor grading are presented in Table ( 3).
As regard response rate to treatment, thirty-six patients had a complete response (72%), nine patients had partial response (18%), one patient had stable disease (2%) and 4 patients had progressive disease (8%).
Table (4) shows the significant prognostic factors for response. The stage of the disease, nodal status and anatomical site were significant prognostic factors for response.
Table (5) shows the toxicity of radiotherapy and its frequency according to RTOG/EROTC toxicity criteria 1995.
Table (6) shows the grades of toxicity of chemotherapy and their frequency according to (NCI) grading of toxicity 1998.
At a median follow-up of 38 months, nine patients (18%) had progression at the tumor site and in four of these patients a recurrence in the lymph nodes of the neck was also observed. Metastases were detected in seven patients (14%), three patients had metastasis in the lung and four in the bone. They were treated by systemic chemotherapy. Three-years overall survival (OS) and disease-free survival (DFS) were 32% and 30%, respectively figure (1, 2).
Prognostic factors for survival were performance status, anatomical site, nodal status, pathological grade and stage of the disease (Figures 3-7) .
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In months In months ‫ס‬ = censored patients ‫ס‬ = censored patients ‫ס‬ = censored patients ‫ס‬ = censored patients ‫ס‬ = censored patients ‫ס‬ = censored patients In months ‫ס‬ = censored patients Figure 7 : Nodal state as a prognostic factor for survival of 50 patients with locally advanced head and neck cancer treated by alternating chemoradiotherapy (node -ve vs. node +ve, P <.001). dIScuSSIon Alternating chemotherapy and radiotherapy has been tested in advanced head and neck cancer and has shown superiority over standard radiation in some randomized trials with only marginally greater toxicity 10 . The biological mechanisms of interaction between chemotherapy and radiotherapy include interactions at the molecular, cellular and tissue levels. At the molecular level, radiation and drugs cooperate to target DNA, by increasing DNA damage and interfering with DNA repair. At the cellular level, chemoradiation may induce cytokinetic cooperation. Radiosenstivity changes during the phases of the cell cycle. The S-phase is the most radioresistant, whereas S-phase cells are highly sensitive to several anticancer drugs. This is the reason why a greater cell kill is observed when proliferating cells are exposed to drugs and radiation in close temporal proximity 11 .
There is one additional mechanism of action that may be ascribed to ACR. The breaks between radiotherapy treatments (that result in tumor repopulation) are filled up with chemotherapy. Therefore, a cytokinetic mechanism of cooperation, exploiting tumor repopulation, may be at work in ACR 12 .
At the tissue level, cooperation between radiation and the chemotherapy drugs is the result of rapid tumor shrinkage and reoxygenation resulting from an improved blood supply. This effect could be related to a reduction in interstitial pressure 13 .
The present study design is similar to the original trials used vinblastine, bleomycin and methotrexate (VBM) and radiotherapy was delivered as a standard single daily fraction in an alternating schedule 14 . The present study shows a complete response (CR) 72%, disease-free survival (DFS) and overall survival (OS) at 3years, 32% and 30%, respectively. This is not in agrement with the results of Merlano et al. 14 who used the same schedule and reported CR 33%, DFS and OS at 4 years 12% and 22%, respectively. The difference may be due to the high percentage of patients with stage IV in his study.
The schema of VBM was replaced with the combination of cisplatin and fluorouracil in light of the accepted superiority of this regimen. Fluorouracil was added to cisplatin because of the supposed synergism between the two drugs. More over, it was delivered as an IV bolus to minimize mucosal toxicity, which is mainly induced by the continuous infusion of the drug. In this way, the overlapping mucosal toxicity between chemotherapy and radiotherapy is intheory reduced 10 .
Two studies used ACR schedule with the combination of cisplatin and fluorouracil. The first one done by Merlano et al. 5 who compare ACR and radiotherapy alone, CR was achieved in 42%, 3years OS was 41% which were significantly higher than radiotherapy alone. The second study was done by Corvo et al. 15 who reported 3years OS 37% and DFS 35%. The lower OS and DFS in the present study compared with their results may be due to the high percentage of hypopharyngeal carcinoma 44%, high percentage of grade III carcinoma 42% and non-surgical management of locoregional recurrence in the present study.
Alternating chemoradiotherapy in locally advanced HNC, regardless of the chemotherapy regimens is more likely to be associated with complete response 16 . To increase the response of ACR induction chemotherapy was given before it as in the study done by Benasso et al. 17 who reported CR86.7%, PR13.3%, 3years DFS and OS, 64% and 83%, respectively.
An investigational program to explore a modified alternating regimen (cisplatin+ fluorouracil) was done by Benasso et al. 18 including gemcitabine given both with radiosenstizing and cytotoxic intent. Complete response was achieved in 72%, 3years OS and DFS was 43% and 39%, respectively. Data of locoregional control favorably compared with those from database of patients treated with alternating cisplatin-fluorouracil and radiation within controlled clinical trials (64% versus 40%).
Another trial done by Benasso et al. 19 who added gemcitabine to the alternating cisplatin-fluorouracil and reported that the addition of gemcitabine at low dose (50mg/m 2 on each Monday of radiotherapy) is feasible and very active. It may improve long-term outcomes despite an acceptable increase of acute mucosal toxicity.
The combination of chemotherapy and radiotherapy inevitably induces more toxic effects than each modality alone. Stomatitis is the major toxic effect of ACR and appears to be strictly related to the chosen drugs and scheduling. Merlano et al. 14 who used VBM schedule reported a grade III-IV stomatitis 31%. Corvo et al. 15 and Fuwa et al. 20 reported 33% and 31% grade III-IV stomatitis with cisplatin-fluorouracil regimen in ACR schedule, all these results are inagrement with the results of the present study.
The addition of gemcitabine to ACR schedule resulted in 81% of 47 treated patients to develop grade III-IV stomatitis which is much higher than the previous results. This can be explained by the use of gemcitabine as a radiosentizer and cytotoxic drug. Another published phase II trial based on ACR done by Merlano et al. 21 who added paclitaxel to cisplatin-fluorouracil and grade III-IV stomatitis occurred in 81% of the 31 treated patients.
A direct comparison between ACR and concurrent chemoradiation (CCR) does not exist, but some studies reported a similar response in both schedules. A study done by Cohen et al. 22 who used fluorouracil+hydroxyurea with hyperfractionated radiotherapy, the other study done by Adelstein et al. 23 who used concurrent cisplatinfluorouracil and conventional radiotherapy. Both studies show the same response to therapy as ACR.
As regard one-year DFS and OS in the present study which was 70% and 78%, respectively, it is comparable with the one-year DFS and OS of the study done by Montejo et al. 24 which was 73% and 73%, respectively on CCR, but the 2-years DFS and OS in his study was 73% and 65% which is higher than the present study this is may be due to the use of IMRT in his trial.
In a study done by Specenier et al. 25 who used CCR and reported a high percentage of non-hematological toxicity, and also Watkins et al. 26 reported a grade III mucositis, nausea and neutropenia, 61%, 27% and 81%, respectively which is higher than the present study. This suggests a more favorable toxicity profile of ACR.
As regard the prognostic factors for response to treatment with ACR in the present study, the anatomical site (P=0.04), nodal stage (P=0.002) and stage of the disease (P=0.003) were significant prognostic factors. This is in agrement with the results reported by Benasso et al. 16 who revealed that the size of the primary tumor (P=0.004), nodal involvement (P=0.02) and performance status (P=0.009) are prognostic variables affecting the probability of achieving a complete response.
Prognostic factors significant for survival in the present study were performance status, pathological grade, anatomical site, stage of the disease and nodal stage. This is inagrement with the results reported by Khademi et al. 27 according to their multivariate analysis of OS, patients under 40 years, node stage and stage of the disease were significant prognostic factors. Another study done by Vermorken et al. 28 revealed that tumor differentiation, ECOG performance status, weigh loss and location of the primary were significant prognostic factors.
concLuSIon Alernating chemotherapy and radiotherapy shows a promising activity and low toxicity in locally advanced head and neck cancer treatment. However, a randomized trials comparing alternating chemoradiation with concurrent chemoradiation are mandatory in order to definitely establish the role of these two different schedules of chemoradiation. 
